MedLumics Secures €34 Million Series B Funding to Illuminate the Future of Healthcare

MedLumics, S.L., a pioneering medical device company dedicated to transforming the latest advancements in biophotonics into innovative and quality products, is thrilled to announce that it has successfully raised €34,000,000 in its latest funding round. This significant capital injection will accelerate the company’s mission—to enhance healthcare through the development and application of groundbreaking imaging techniques, specifically by advancing Optical Coherence Tomography (OCT). As a light-based diagnostic tool with a rapidly expanding footprint, OCT is revolutionizing the way clinicians visualize and diagnose various conditions, and MedLumics is at the forefront of harnessing its potential. With this substantial investment, the company is poised to expand its research, development, and clinical validation efforts, enabling it to innovate further and refine its disruptive technological advantages that set it apart in the medical imaging industry. The funds will not only bolster MedLumics’ existing portfolio of products but also support the exploration of new clinical applications, ensuring that healthcare providers have access to state-of-the-art imaging modalities capable of delivering superior diagnostic accuracy and enhanced patient outcomes. This critical boost paves the way for increased collaboration with healthcare professionals worldwide, further propelling the adoption of this key diagnostic technique. MedLumics remains committed to its mission of “Enlightening Healthcare” by continuously pushing the boundaries of what light-based diagnostics can achieve, ultimately striving to improve the quality of life for patients around the globe. This funding milestone marks a new chapter in the company’s evolution as it continues to inspire innovation, drive progress, and redefine the future of medical diagnostics.